INS and diabetes mellitus: Earlier studies have coherently reported that blockade of TRPV1 in rodents with type 2 diabetes halted disease progression [30], thus indicating that a TRPV1 antagonist may be a therapeutic target for the disease progression of diabetes by improving glucose intolerance and correcting dysfunctional insulin secretion [30].